Issue link: https://beckershealthcare.uberflip.com/i/1425344
18 Executive Briefing As the field of spine surgery become more aware of the factors that contribute to improved short- and long-term patient outcomes, we are constantly evaluating and improving our surgical techniques and the devices we use to help us achieve these outcomes. By seamlessly integrating the Catalyft™ PL cage with the latest technologies, surgeons can obtain immediate feedback during the planning and placement of the cage within the disc space. I can't think of anything more satisfying to a spine surgeon than real-time feedback for a patient on the operating room table that permits appropriate adjustments to be made on the fly. CH: The compatibility of the Catalyft™ PL expandable interbody device with the StealthStation™ S8 navigation system facilitates precise placement of the cage within the disc space. Navigated interbody cage insertion allows surgeons to achieve ideal implant position. Further, visualization of the implant in both the collapsed and fully expanded positions provides a virtual representation of the potential sagittal correction achievable. Q: A common drawback associated with expandable interbody cages is related to the delivery of autogenous bone graft and/or allograft bone graft material especially once the cage is expanded. How does the design of the Catalyft™ PL expandable interbody device facilitate bone graft delivery? SR: The biggest challenge with expandable cages has historically been concerns with the "biologic gap" that can occur when an expandable cage is expanded. The Catalyft™ PL expandable interbody device is integrated with the Grafton™ DBF Inject graft delivery system, which I feel allows spine surgeons a more consistent and easier way to place bone graft directly around, through and into the interbody cage. I find this graft delivery system to be simple to load and very smooth in delivering the bone graft where needed, thus eliminating the potential for any biologic voids in the disc space or created by the cage's expansion. CH: While some implants have a mechanism for backfilling of the cage, Catalyft™ PL expandable interbody device goes even further. Not only can the biologic be delivered into the interbody cage following expansion, but the entire disc space can be filled through the cage. This can facilitate maximal biologic packing of the disc space both within and around the expanded Catalyft™ PL expandable interbody device. Further, eliminating pre-packing of the disc space can avoid compaction of the graft in front on the cage on insertion, which can at times limit anterior placement of the cage. Conclusion These surgeons see advantages in the Catalyft™ PL expandable interbody device. The design provides ease of insertion and offers surgeons flexibility based on their cage type preferences. Further, both surgeons see advantages in the Catalyft™ PL expandable interbody device's compatibility with the StealthStation™ S8 navigation system, which facilitates precise placement of the cage within the disc space. To reiterate Dr. Rajpal's statement, "I can't think of anything more satisfying to a spine surgeon than real-time feedback for a patient on the operating room table that permits appropriate adjustments to be made on the fly." The favorable reactions and experiences of these two spine surgeons describe how the features of the Catalyft™ PL expandable interbody device may provide certain advantages as surgeons are executing their surgical plans. n INDICATIONS The Catalyft™ PL expandable interbody system is indicated for use as an intervertebral body fusion device in skeletally mature patients with degenerative disc disease (DDD - defined by discogenic back pain with degeneration of the disc confirmed by patient history and radiographic studies) at one or two contiguous levels of the lumbar spine (L2-S1). These DDD patients may also have up to Grade 1 spondylolisthesis or retrolisthesis at the involved levels. Additionally, the Catalyft™ PL expandable interbody system can be used with patients diagnose with spinal deformities as an adjunct to fusion. These patients should be skeletally mature and have undergone 6 months of non-operative treatment prior to surgery. Implants are used to facilitate fusion in the lumbar spine using autogenous bone graft and/or allograft bone graft comprised of cancellous and/or corticocancellous bone, and/or demineralized allograft bone with bone marrow aspirate. These implants are intended for use with supplemental internal fixation systems. DISCLAIMERS This content is sponsored by Medtronic and contains the opinions of and personal surgical techniques practiced by Drs. Holland and Rajpal. The opinions and techniques presented herein are for information purposes only and the decision of which techniques to use in a particular surgical application should be made by the surgeon based on the individual facts and circumstances of the patient and previous surgical experience. Drs. Holland and Rajpal are paid consults for Medtronic. This interview, sponsored by Medtronic, is intended to educate, and train customers regarding the approved or cleared uses of Medtronic products. As such, unapproved products or indications are not discussed herein. You may contact Medtronic's Office of Medical Affairs at 800.876.3133 ext. 6044 for any specific clinical questions you may have. We lead global healthcare technology. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ people. Transforming the lives of two people every second, every hour, every day. Medtronic. Engineering the extraordinary.